1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies

Wedgewood Partners Comments on Perrigo

August 31, 2012 | About:

Perrigo (NYSE:PRGO) positively contributed to performance during the quarter after the Company reported a 32% increase in adjusted income from continuing operations and subsequently received FDA approval for five new prescription and over-the-counter (OTC) pharmaceuticals. Over $15 billion in OTC pharmaceuticals will lose patent protection over the next several years and Perrigo, as the largest manufacturer of private-label, OTC pharmaceuticals, will have ample opportunity to provide its value-added services to retailers around the globe. During the quarter, shares of the company traded to valuation levels that were not as attractive as they have been in the past, so we trimmed positions in Perrigo.

From Tony Guerrerio's second quarter letter.


Rating: 2.4/5 (8 votes)

Comments

Please leave your comment:


Performances of the stocks mentioned by


User Generated Screeners


nec5555Pat Dorsey Moat 5Y v1
nec5555Pat Dorsey Moat 5Y
alexbernal0$$SharYieldScore
alexbernal0$$FCFScore
alexbernal0$$EarnGrowScore
fluidityinglassShort%20Squeeze%20high%20F,%20
opadovaniP Median2 No DIV
cegdevelopmentthe best managers
cegdevelopmentprof managers
cegdevelopmentguru goals
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK